About Us
Cancer of the prostate is the second leading
cause of male cancer death in the United States.
Approximately 220,000 new cases will be diagnosed this year and nearly
30,000 men will
die
from the disease. Despite the gravity of a prostate
cancer diagnosis, there is a surprising amount of
good news to report about this disease
today.
First, although statistics show prostate cancer
is on the rise, we know much of this is due to a
dramatic increase in early detection. Screening
procedures are more common and heightened public
awareness has helped more men ask their doctors to be tested.
Second, extensive research in
this field of medicine has lead to great advances
in treatment and care of prostate cancer patients. And
third, these new treatment options,
the most remarkable of which is called brachytherapy
have profoundly improved the standards for quality
of life.
The Dattoli Cancer Foundation was
established in 2000 to help increase awareness about the importance
of PSA screening;
to offer current, accurate
information about leading edge treatment for prostate
cancer; and to foster research into even better treatment
options.
The
Foundation is named for Dr. Michael Dattoli, a living
pioneer in the field of brachytherapy for the treatment of prostate
cancer. Dr. Dattoli and his partner Dr. Richard Sorace are
credited with many advances
in refining and targeting external beam radiation
and precise intra- and extracapsular radioactive seed placement.
At the time of the creation
of this Foundation, the Dattoli Team has treated
over 7,000 men from all corners of the world. Dr. Dattoli
is a frequent lecturer and author
of a number of textbooks and journal articles.
The Dattoli
Cancer Center and Brachytherapy Research Institute
in Sarasota, Florida, is unparalleled anywhere in
the world for its combination of
state-of-the-art technology and clinical expertise.
For more information about Drs. Dattoli and Sorace
as well as the Dattoli Cancer Center, visit www.dattoli.com.
Staff members
of the Foundation include Ginya Carnahan, CPRC, Director
of Development, and Amber Kawlewski, Patient Programs
Director. Together this team strives to offer support, hope and
education to prostate cancer patients and their families.
|